Specific T- Lymphocytes

PreclinicalBiologic

PPaul Szabolcs

Specific T- Lymphocytes is one of 4 biologic programs targeting Adenovirus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenovirusEnrolling by invitation

AdenovirusPreclinical

Enrolling by invitation

Competition

Competitive Landscape

5 competitors in Adenovirus

#DrugCompanyPhaseTrials

Adenovirus Specific T- Lymphocytes

JJessie L. Alexander

Phase 2

1 2

Cytotoxic T-Lymphocytes

NNew York Medical College

Phase 2

1 3

Cytomegalovirus Specific T-Lymphocytes

JJessie L. Alexander

Phase 2

1 4

Specific T- Lymphocytes

PPaul Szabolcs

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adenovirus1 trial

Anti-viral T-cell Therapy by Gamma Capture for High-risk Patients With Acquired or Inherited Immune Defects

Enrolling by invitation·PPaul Szabolcs·Preclinical·NCT06027879·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Specific T- Lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Specific T- Lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Specific T- Lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paul Szabolcs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: PPaul Szabolcs

Specific T- Lymphocytes

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adenovirus1 trial

References

Drug Info

Quick Facts

Related News